Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2021 07:30 ET | Source: MediWound Ltd.

EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid

YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
November 18, 2021 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa

NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second...
November 18, 2021 07:30 ET | Source: Artizan Biosciences, Inc.

Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease

NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, and Biohaven Therapeutics Ltd....
November 18, 2021 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery

PETAH TIKVA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally...
November 18, 2021 07:00 ET | Source: Amicus Therapeutics, Inc.

The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed...
November 18, 2021 07:00 ET | Source: Orchard Therapeutics (Europe) Limited

Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome

100 percent overall survival with median follow-up of two years post-treatment with HSC gene therapy Preliminary findings show promising metabolic and early clinical outcomes Results warrant further...
November 18, 2021 07:00 ET | Source: Adicet Bio

Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors

MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
November 18, 2021 06:35 ET | Source: Immuneering Corporation

Immuneering Announces Participation in December Investor Conferences

CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
November 18, 2021 06:30 ET | Source: Centogene NV

CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
November 18, 2021 06:00 ET | Source: Purity-IQ Inc

Cannabis Authenticity & Purity Standard Auditor Certification Commences

GUELPH, Ontario and SYDNEY, Australia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- The Cannabis Authenticity and Purity Standard (CAPS) Auditor certification was officially launched for global applications....